Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer

NCT05624996 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT05624996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05624996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer
Lead sponsor
NRG Oncology
Phase
Phase 3
Overall status
Recruiting
Start date
July 12, 2023
Completion date
October 15, 2036
Enrollment
474 (estimated)
Sites
477

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced lung non-small cell carcinoma, stage iib lung cancer ajcc v8, stage iii lung cancer ajcc v8